Clinical Trial

A Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC

Study acronym: ACADEMY
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study aims to evaluate the efficacy and safety of Apatinib and Adebrelimab in Combination With chemotherapy in patients with advanced intrahepatic cholangiocarcinoma (ICC)
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-04-06; most recent amendment 2026-06-15.
Trial Details
NCT Number NCT06925516
Lead Sponsor Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Collaborators: Jiangsu HengRui Medicine Co., Ltd.
Conditions Intrahepatic Cholangiocarcinoma (Icc)
Enrollment 38 participants
Start Date 2025-04-25
Primary Completion 2027-06-01 (estimated)
Study Completion 2028-10-01 (estimated)
Updated on ClinicalTrials.gov 2026-06-17